利民股份(002734.SZ):半年度淨利潤預降60.35%-63.65%
格隆匯7月16日丨利民股份(002734.SZ)公佈,預計2023年半年度歸屬於上市公司股東的淨利潤5500萬元-6000萬元,同比下降60.35%-63.65%;扣除非經常性損益後的淨利潤4900萬元-5200萬元,同比下降63.69%-65.78%。
2023年上半年,業績較上年同期減少的主要原因:上半年農化行業整體渠道庫存過大,國內外終端客户需求下滑,公司主要產品銷售價格呈下降趨勢,導致盈利能力減弱。為積極應對挑戰,公司持續聚焦重點客户、加強戰略合作、積極開拓市場,加強營銷隊伍建設,降低原材料採購成本、降本增效,推進新產品小試及工業化進度,進一步提高公司整體盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.